A quantitative immunoassay for lung cancer biomarker CIZ1b in patient plasma.

ABSTRACT:

Objectives

Non-invasive tests for early detection of lung cancer are an important unmet clinical need. CIZ1b plasma biomarker can discriminate stage 1 lung cancer from within high-risk groups with clinically useful accuracy, with ROC AUCs in excess of 0.9 for two independent retrospective cohorts, and could therefore meet this need. Our aim was to characterise the native state of the biomarker and develop a quantitative immunoassay.

Design and methods

Selective denaturation, preparative electrophoresis and mass spectrometry of human plasma were used to characterise the biomarker and interaction partners. A sandwich ELISA was generated, and specificity for CIZ1b biomarker tested on lung cancer patient plasma.

Results

CIZ1b biomarker is a denaturation-resistant complex

SUBMITTER: Coverley D 

PROVIDER: S-EPMC5441127 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature